These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 28633708)

  • 1. Once-daily dosing of amikacin for treatment of
    Lee H; Sohn YM; Ko JY; Lee SY; Jhun BW; Park HY; Jeon K; Kim DH; Kim SY; Choi JE; Moon IJ; Shin SJ; Park HJ; Koh WJ
    Int J Tuberc Lung Dis; 2017 Jul; 21(7):818-824. PubMed ID: 28633708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases.
    Yagi K; Ishii M; Namkoong H; Asami T; Iketani O; Asakura T; Suzuki S; Sugiura H; Yamada Y; Nishimura T; Fujiwara H; Funatsu Y; Uwamino Y; Kamo T; Tasaka S; Betsuyaku T; Hasegawa N
    BMC Infect Dis; 2017 Aug; 17(1):558. PubMed ID: 28793869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of amikacin on cell wall glycopeptidolipid synthesis in Mycobacterium abscessus.
    Lee SY; Kim HY; Kim BJ; Kim H; Seok SH; Kim BJ; Kook YH
    J Microbiol; 2017 Aug; 55(8):640-647. PubMed ID: 28752292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a One-Step Multiplex PCR Assay for Differential Detection of Major Mycobacterium Species.
    Chae H; Han SJ; Kim SY; Ki CS; Huh HJ; Yong D; Koh WJ; Shin SJ
    J Clin Microbiol; 2017 Sep; 55(9):2736-2751. PubMed ID: 28659320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Review and Meta-analyses of the Effect of Chemotherapy on Pulmonary Mycobacterium abscessus Outcomes and Disease Recurrence.
    Pasipanodya JG; Ogbonna D; Ferro BE; Magombedze G; Srivastava S; Deshpande D; Gumbo T
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-Resistant Mycobacterium abscessus Lung Disease.
    Choi H; Kim SY; Kim DH; Huh HJ; Ki CS; Lee NY; Lee SH; Shin S; Shin SJ; Daley CL; Koh WJ
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biofilm colonization of Mycobacterium abscessus: New threat in hospital-acquired surgical site infection.
    Ghosh R; Das S; Kela H; De A; Haldar J; Maiti PK
    Indian J Tuberc; 2017 Jul; 64(3):178-182. PubMed ID: 28709485
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Tortoli E; Kohl TA; Trovato A; Baldan R; Campana S; Cariani L; Colombo C; Costa D; Cristadoro S; Di Serio MC; Manca A; Pizzamiglio G; Rancoita PMV; Rossolini GM; Taccetti G; Teri A; Niemann S; Cirillo DM
    Eur Respir J; 2017 Jul; 50(1):. PubMed ID: 28705942
    [No Abstract]   [Full Text] [Related]  

  • 9. In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates.
    Huang CC; Wu MF; Chen HC; Huang WC
    J Microbiol Immunol Infect; 2018 Oct; 51(5):636-643. PubMed ID: 28705770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of LCB01-0371, a Novel Oxazolidinone, against Mycobacterium abscessus.
    Kim TS; Choe JH; Kim YJ; Yang CS; Kwon HJ; Jeong J; Kim G; Park DE; Jo EK; Cho YL; Jang J
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674049
    [No Abstract]   [Full Text] [Related]  

  • 11. Amikacin exposure and susceptibility of macrolide-resistant
    Daniel-Wayman S; Shallom S; Azeem N; Olivier KN; Zelazny AM; Prevots DR
    ERJ Open Res; 2019 Apr; 5(2):. PubMed ID: 31149626
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.
    Daley CL; Iaccarino JM; Lange C; Cambau E; Wallace RJ; Andrejak C; Böttger EC; Brozek J; Griffith DE; Guglielmetti L; Huitt GA; Knight SL; Leitman P; Marras TK; Olivier KN; Santin M; Stout JE; Tortoli E; van Ingen J; Wagner D; Winthrop KL
    Clin Infect Dis; 2020 Aug; 71(4):e1-e36. PubMed ID: 32628747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada.
    Aznar ML; Marras TK; Elshal AS; Mehrabi M; Brode SK
    BMC Pharmacol Toxicol; 2019 Jun; 20(1):37. PubMed ID: 31159865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.
    Daley CL; Iaccarino JM; Lange C; Cambau E; Wallace RJ; Andrejak C; Böttger EC; Brozek J; Griffith DE; Guglielmetti L; Huitt GA; Knight SL; Leitman P; Marras TK; Olivier KN; Santin M; Stout JE; Tortoli E; van Ingen J; Wagner D; Winthrop KL
    Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32636299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Outcomes of Clofazimine-Containing Regimens in Severe
    Lee I; Hwang EJ; Kim JY; Yim JJ; Kwak N
    Open Forum Infect Dis; 2024 Feb; 11(2):ofad682. PubMed ID: 38328494
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Ahmad MN; Garg T; Singh S; Shukla R; Malik P; Krishnamurthy RV; Kaur P; Chopra S; Dasgupta A
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0056422. PubMed ID: 36445129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addressing antimicrobial resistance with the IDentif.AI platform: Rapidly optimizing clinically actionable combination therapy regimens against nontuberculous mycobacteria.
    Mukherjee D; Wang P; Hooi L; Sandhu V; You K; Blasiak A; Chow EK; Ho D; Ee PLR
    Theranostics; 2022; 12(16):6848-6864. PubMed ID: 36276648
    [No Abstract]   [Full Text] [Related]  

  • 18. ASK1 is a novel molecular target for preventing aminoglycoside-induced hair cell death.
    Ogier JM; Gao Y; Dunne EM; Wilson MA; Ranganathan SC; Tesch GH; Nikolic Paterson DJ; Dabdoub A; Burt RA; Nayagam BA; Lockhart PJ
    J Mol Med (Berl); 2022 May; 100(5):797-813. PubMed ID: 35471608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Molecular Therapeutic Agents and Drug Candidates for
    Quang NT; Jang J
    Front Pharmacol; 2021; 12():724725. PubMed ID: 34526902
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis.
    Burke A; Smith D; Coulter C; Bell SC; Thomson R; Roberts JA
    Clin Pharmacokinet; 2021 Sep; 60(9):1081-1102. PubMed ID: 33982266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.